Vigil Neuroscience Inc

NASDAQ VIGL

Data sourced from

and

Download Data

Vigil Neuroscience Inc Working Capital Turnover Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Vigil Neuroscience Inc Working Capital Turnover Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate revenue. It is calculated by dividing the revenue by the working capital. This ratio indicates the number of times the company's working capital is converted into revenue during a specific period. A higher working capital turnover ratio suggests more efficient utilization of working capital in revenue generation. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Vigil Neuroscience Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
Vigil Neuroscience Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
Vigil Neuroscience Inc Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00.

NASDAQ: VIGL

Vigil Neuroscience Inc

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
IPO Date	Jan. 7, 2022
Location	United States
Headquarters	1 Broadway, Cambridge, MA, United States, 02142
Employees	65
Sector	Healthcare
Industry	Biotechnology

Description

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Key trends